Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 170

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers

Natrajan, Rachael, Lambros, Maryou B., Rodríguez-Pinilla, Socorro María, Moreno-Bueno, Gema, Tan, David S.P., Marchió, Caterina, Vatcheva, Radost, Rayter, Sydonia, Mahler-Araujo, Betania, Fulford, Laura G., Hungermann, Daniela, Mackay, Alan, Grigoriadis, Anita, Fenwick, Kerry, Tamber, Narinder, Hardisson, David, Tutt, Andrew, Palacios, Jose, Lord, Christopher J., Buerger, Horst, Ashworth, Alan, Reis-Filho, Jorge S.·2009·Clinical Cancer Research

Abstract

Purpose: To characterize the molecular genetic profiles of grade 3 invasive ductal carcinomas of no special type using high-resolution microarray-based comparative genomic hybridization (aCGH) and to identify recurrent amplicons harboring putative therapeutic targets associated with luminal, HER-2, and basal-like tumor phenotypes. Experimental Design: Ninety-five grade 3 invasive ductal carcinomas of no special type were classified into luminal, HER-2, and basal-like subgroups using a previously validated immunohistochemical panel. Tumor samples were microdissected and subjected to aCGH using a tiling path 32K BAC array platform. Selected regions of recurrent amplification were validated by means of in situ hybridization. Expression of genes pertaining to selected amplicons was investigated using quantitative real-time PCR and gene silencing was done using previously validated short hairpin RNA constructs. Results: We show that basal-like and HER-2 tumors are characterized by “sawtooth” and “firestorm” genetic patterns, respectively, whereas luminal cancers were more heterogeneous. Apart from confirming known amplifications associated with basal-like (1q21, 10p, and 12p), luminal (8p12, 11q13, and 11q14), and HER-2 (17q12) cancers, we identified previously unreported recurrent amplifications associated with each molecular subgroup: 19q12 in basal-like, 1q32.1 in luminal, and 14q12 in HER-2 cancers. PPM1D gene amplification (17q23.2) was found in 20% and 8% of HER-2 and luminal cancers, respectively. Silencing of PPM1D by short hairpin RNA resulted in selective loss of viability in tumor cell lines harboring the 17q23.2 amplification. Conclusions: Our results show the power of aCGH analysis in unraveling the genetic profiles of specific subgroups of cancer and for the identification of novel therapeutic targets.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-08-1878

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 170

Metadata

Authors
Natrajan, R., Lambros, M. B., Rodríguez-Pinilla, S. M., Moreno-Bueno, G., Tan, D. S. P., Marchió, C., Vatcheva, R., Rayter, S., Mahler-Araujo, B., Fulford, L. G., Hungermann, D., Mackay, A., Grigoriadis, A., Fenwick, K., Tamber, N., Hardisson, D., Tutt, A., Palacios, J., Lord, C. J., Buerger, H., Ashworth, A., & Reis-Filho, J. S.
Venue
Clinical Cancer Research
Published
2009-04-15
Volume
15
Issue
8
Pages
2711-2722
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2129315871
Cited by
170
References
1
FWCI
8.94
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-08-1878
The paper
Natrajan, R., Lambros, M. B., Rodríguez-Pinilla, S. M., Moreno-Bueno, G., Tan, D. S. P., Marchió, C., Vatcheva, R., Rayter, S., Mahler-Araujo, B., Fulford, L. G., Hungermann, D., Mackay, A., Grigoriadis, A., Fenwick, K., Tamber, N., Hardisson, D., Tutt, A., Palacios, J., Lord, C. J., . . . Reis-Filho, J. S. (2009). Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-08-1878

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.